Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the effect of a new drug on the composition of the urine in
kidney stone patients. This new drug (Jardiance®, substance: empagliflozin) is currently
approved in Switzerland for the treatment of patients with diabetes. Data from previous
studies with and without diabetes suggest that it may have a beneficial effect on the
composition of the urine and thereby reduce the risk of developing kidney stones.